Cefepime Coverage for H. influenzae and M. catarrhalis
Yes, cefepime provides excellent coverage for both Haemophilus influenzae and Moraxella catarrhalis, including β-lactamase-producing strains. According to the FDA label, cefepime demonstrates in vitro activity against both organisms with at least 90% of isolates exhibiting MICs at or below the susceptible breakpoint 1.
Microbiological Activity
Cefepime's spectrum explicitly includes both target organisms:
H. influenzae: Cefepime shows complete susceptibility (100%) with MIC₉₀ values of 0.015-0.25 μg/mL, regardless of β-lactamase production 2, 3, 4. The FDA label lists H. influenzae among organisms for which cefepime has been shown active both in vitro and in clinical infections 1.
M. catarrhalis: The FDA label specifically lists M. catarrhalis as an organism against which cefepime demonstrates activity, with MIC₉₀ values of 0.12-2.0 μg/mL 1, 3, 4. Cefepime maintains activity against β-lactamase-producing strains, which represent 90-100% of M. catarrhalis isolates 5.
Mechanism of β-lactamase Resistance
Cefepime's effectiveness against these organisms stems from its structural properties:
- Cefepime exhibits high resistance to hydrolysis by most β-lactamases and demonstrates rapid penetration into Gram-negative bacterial cells 1.
- It has low affinity for chromosomally-encoded β-lactamases and shows no inducing capacity 3.
- The zwitterionic quaternized N-methyl-pyrrolidine moiety at the 3' position enables rapid penetration through the outer membrane of Gram-negative bacteria 3.
Comparative Activity
Cefepime performs favorably compared to other cephalosporins:
- Against H. influenzae, cefepime demonstrates equivalent or superior activity to ceftriaxone (both 100% susceptible) and substantially better activity than first-generation cephalosporins, which have poor H. influenzae coverage 5.
- For M. catarrhalis, cefepime's activity is comparable to third-generation cephalosporins like cefixime and superior to second-generation agents like cefuroxime 6.
Clinical Context
Important considerations for clinical use:
- Taiwan guidelines recommend second- or third-generation cephalosporins or fluoroquinolones for β-lactamase-producing H. influenzae, with cefepime meeting these criteria 6.
- Cefepime was found to be the most broad-spectrum cephalosporin analyzed in pediatric infections, maintaining potent activity against contemporary respiratory pathogens 2.
- The drug maintains efficacy even as resistance to other agents (amoxicillin/clavulanate, macrolides, fluoroquinolones) has increased over surveillance periods 7.
Dosing Considerations
Standard dosing provides adequate coverage:
- Adult dosing: 1-2 g IV every 8-12 hours depending on infection severity 1.
- Pediatric dosing (≥2 months): 50 mg/kg every 8-12 hours 1.
- Dose adjustment required for creatinine clearance ≤60 mL/min 1.
Critical caveat: While cefepime covers H. influenzae and M. catarrhalis effectively, insufficient clinical data exist to support its use in pediatric patients for serious infections where H. influenzae type b is the suspected pathogen, particularly in meningitis cases where an alternate agent should be used 1.